Abstract
4589 Background: While neoadjuvant chemotherapy preceding radical surgery (S) for PSCC appears to provide the most optimal outcomes, there are no randomized studies. The impact of triple-modality S plus perioperative chemotherapy (C) plus radiation (XRT) for PSCC is unclear. The differential outcomes provided by perioperative XRT vs. perioperative C are also unclear. Given the absence of prospective trials, we retrospectively analyzed the U.S. National Cancer Database (NCDB) to study this issue. Methods: Data from the NCDB was obtained for pts with locally advanced PSCC from 1998-2011. Patients who underwent S for PSCC pathologic stage ≥1 with data for receipt of perioperative C and/or XRT and follow-up were eligible for analysis. The following variables were evaluated: pathologic stage, age, Charlson Comorbidity Index (CCI), race, overall survival (OS), socioeconomic status based on median income of area of residence and therapy (S+C, S+XRT, S+C+XRT). Treatment patterns were described. Multivariate analyses (MVA) were conducted to determine the impact of factors on OS with P < 0.05 considered significant. Results: A total of 418 pts were evaluable including 132 in the S+XRT group, 166 in the S+C group and 120 in the S+C+XRT group. The number of pts with stages 1, 2, 3, 4 and unknown were 26, 78, 146, 137 and 31, respectively. In the MVA, stage was independently significantly prognostic (p = 0.002), while age (p = 0.056) and CCI (p = 0.057) were trending significant. S+C+XRT was not statistically better than S+XRT (HR 1.37 [95% CI: 0.935 - 2.007]) or S+C (HR 0.834 [95% CI: 0.589 - 1.180]). Additionally, S+C was not associated with significantly different OS compared to S+XRT (HR 1.142 [95% CI: 0.790 - 1.652]). Limitations of a retrospective analysis apply. Conclusions: This is the largest retrospective study of perioperative therapy for locally advanced PSCC. Triple modality therapy (S+C+XRT) did not extend OS compared to dual modality therapy (S+C or S+XRT). Additionally, the analysis did not identify whether C or XRT should be preferred in pts receiving dual modality therapy. The phase II International Penile Cancer Adjuvant Trial (InPACT) will investigate these conundrums for this orphan malignancy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have